Clinical testing is underway, with Fate Therapeutics leading a phase I dose escalation of iPSC-derived CD19 CAR T-cells where the CAR is traduced into a TRAC locus (FT819) against B-cell lymphoma and leukaemia. Here, CD19 is linked to leukemia.